Elicio Therapeutics Inc.
$ 12.18
-0.16%
21 Apr - close price
- Market Cap 224,432,000 USD
- Current Price $ 12.18
- High / Low $ 12.88 / 11.81
- Stock P/E N/A
- Book Value 0.09
- EPS -2.58
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.87 %
- ROE -600.13 %
- 52 Week High 14.93
- 52 Week Low 4.70
About
Elicio Therapeutics Inc. (ELTX) is an innovative clinical-stage biotechnology firm at the forefront of developing transformative immunotherapy solutions for cancer treatment. The company's proprietary Amphiphilic TLR9 Agonist, Eli-002, is designed to stimulate strong immune responses against various cancer types, aiming to significantly improve treatment outcomes for patients. With a strategic emphasis on personalized cancer vaccines and cutting-edge immunotherapeutic strategies, Elicio is well-positioned to address substantial unmet medical needs within oncology, actively advancing its clinical trials to redefine cancer care.
Analyst Target Price
$18.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-13 | 2025-08-07 | 2025-05-13 | 2025-03-27 | 2024-11-07 | 2024-08-13 | 2024-05-15 | 2024-03-29 | 2023-11-09 | 2023-08-11 | 2023-05-10 |
| Reported EPS | -0.49 | -0.6 | -0.66 | -0.87 | -1.02 | -1.39 | -0.64 | -1.15 | -1.75 | -1.27 | -2.4376 | -1.5066 |
| Estimated EPS | -0.445 | -0.68 | -0.67 | -0.73 | -0.875 | -0.73 | -0.96 | -1.09 | -0.78 | -0.8 | None | None |
| Surprise | -0.045 | 0.08 | 0.01 | -0.14 | -0.145 | -0.66 | 0.32 | -0.06 | -0.97 | -0.47 | 0 | 0 |
| Surprise Percentage | -10.1124% | 11.7647% | 1.4925% | -19.1781% | -16.5714% | -90.411% | 33.3333% | -5.5046% | -124.359% | -58.75% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.49 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELTX
2026-04-16 12:09:43
Elicio Therapeutics (Nasdaq: ELTX) announced it granted 21,210 inducement stock options to a new employee on April 15, 2026. The options have an exercise price of $11.78 per share, based on the Nasdaq closing price, and will vest over four years. This grant was approved by the Compensation Committee under the 2024 Inducement Incentive Award Plan and is intended to incentivize the new hire.
2026-04-16 12:09:43
Elicio Therapeutics announced the grant of 21,210 inducement stock options to a new employee on April 15, 2026, as an incentive for employment in accordance with Nasdaq rules. The options, priced at $11.78 per share, vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder ratably thereafter. Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, including its lead program ELI-002 7P for mKRAS-positive cancers.
2026-04-16 04:09:43
This page provides access to Elicio Therapeutics (ELTX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing equity awards to executives (CSO and EVP), a resale registration, and prior quarterly results discussing net loss and cash position. The platform offers AI-powered summaries and sentiment analysis for these regulatory documents.
2026-04-08 12:10:14
This article analyzes the valuation of Elicio Therapeutics Inc (ELTX), suggesting it is currently in the "Fair zone" based on its forward P/S ratio compared to its five-year average. It highlights a significantly higher current Price-to-Book (P/B) ratio and a negative Forward Free Cash Flow (FCF) yield relative to historical averages. The article also notes that ELTX's P/S ratio is above the industry average, which is deemed unsustainable given its revenue growth.
2026-03-28 09:09:46
This article reports that the price target for Elicio Therapeutics (ELTX) has been increased by 12.90% to 17.85. The information is sourced from MSN.
2026-03-23 06:39:48
This article analyzes the historical performance of Elicio Therapeutics, Inc. (ELTX) stock, showing investment returns over 1, 5, and 10 years, and comparing its annual performance against the S&P 500. It also provides a detailed overview of Elicio Therapeutics, including its focus on novel immunotherapies for cancer, its proprietary Amphiphile (AMP) platform, its lead product candidate ELI-002 for mKRAS-driven cancers, and its clinical focus on high-risk pancreatic and colorectal cancers. The company's pipeline beyond ELI-002, its off-the-shelf immunotherapy strategy, industry classification, and research collaborations are also discussed.
